IL17A and Alzheimer disease 18: Considering that PPARγ is a negative regulator of IL-17 and could improve the clinical symptoms of AD18, we investigated the role of PPARγ using NC/Nga mice and IL-17-stimulated RAW264.7 cells to the best of our knowledge on PB.